Thursday, March 12, 2015
inVentiv Health, a global provider of clinical, commercial and consulting services, announced that its existing CRO, PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the clinical segment and inVentiv’s commercial and consulting services.
PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Dr. Susan C. Stansfield as executive vice president of clinical operations for phase II-IV development in Europe, Middle East and Africa (EMEA), Asia-Pacific and Latin America.
Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.
PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.